Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022
One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor outcomes and overall survival maintained compared to placebo
Related news for (GRTX)
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals
- Galera Announces Board Approval of Complete Liquidation and Dissolution
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
- Galera Adopts Limited Duration Stockholder Rights Agreement
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates